Amphastar Pharmaceuticals (AMPH) EBITDA Margin (2013 - 2026)

Amphastar Pharmaceuticals' EBITDA Margin history runs 14 years deep, the most recent figure standing at 7.96% for Q1 2026.

• In Q1 2026, EBITDA Margin fell 1391.0% year-over-year to 7.96%; the TTM figure through Mar 2026 stood at 0.32% (down 2633.0% YoY), while the FY2025 annual figure was 3.61%, down 2446.0% from the prior year.
• EBITDA Margin was 7.96% for Q1 2026 at Amphastar Pharmaceuticals, up from 43.06% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 40.25% in Q3 2023 to a low of 43.06% in Q4 2025.
• Historically, EBITDA Margin has averaged 20.09% across 5 years, with a median of 24.19% in 2025.
• The sharpest annual moves came in 2023 and 2025: EBITDA Margin jumped 2092 bps in 2023, then plunged 6726 bps in 2025.
• A 5-year view of EBITDA Margin shows it stood at 28.02% in 2022, then increased by 8 bps to 30.31% in 2023, then fell by 20 bps to 24.2% in 2024, then sank by 278 bps to 43.06% in 2025, then jumped by 118 bps to 7.96% in 2026.
• The last three EBITDA Margin figures came in at 7.96% (Q1 2026), 43.06% (Q4 2025), and 13.2% (Q3 2025), per Business Quant data.